Antibody fragments like Fab, ScFv, and VHH are emerging stars in antibody drug development, utilized both as standalone molecules and as building blocks of bispecific antibodies. However, their production and engineering face numerous challenges, including issues related to yield, purity, throughput, and stability. In this presentation, we will unveil innovative strategies to overcome these challenges, tailored to the distinctive characteristics of Fab, ScFv, and VHH. We’ll provide key insights into molecular design, high-titer CHO transient and stable production and effective purification methods to accelerate your development of antibody fragments.